Research

Hormonal

Adding luseogliflozin (an SGLT2 inhibitor) to incretin modulator therapy produces an additive glucose-lowering effect, specifically reducing time above range, with the magnitude of benefit being significantly greater in patients consuming high-carbohydrate diets compared to low-carbohydrate diets.

If you are taking an incretin-based diabetes medication (like a GLP-1 agonist or DPP4 inhibitor) and consume a diet high in carbohydrates (e.g., >180g carbs daily), adding luseogliflozin (2.5mg daily) may provide better blood sugar control than adding it to a low-carb diet. This combination appears to work additively, meaning the drugs complement each other to handle the glucose load from carbs more effectively than either might alone in that specific context.

ModerateQualifiesMEDIUM confidence
In this study, the observed number was small; however, combined treatment with an incretin modulator and luseogliflozin had an additive effect in high- versus low-carbohydrate intake, indicating the possible effectiveness of the combined therapy.
Gendai Lee · Cureus · 2022

Why this rating

Small sample size (n=35), single-center, short duration (2 weeks), and lack of blinding reduce the strength of evidence.

Source

Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet

Gendai Lee · Cureus · 2022

DOI 10.7759/cureus.30410

cohort · n=35
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →